X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The funding will be used to support Phase II clinical development of BioAge’s lead compound BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: BGE-105
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sofinnova Investments
Deal Size: $170.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing February 13, 2024
Details:
As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: BGE-105
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
